These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29391065)

  • 21. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
    Bays HE; Schwartz S; Littlejohn T; Kerzner B; Krauss RM; Karpf DB; Choi YJ; Wang X; Naim S; Roberts BK
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2889-97. PubMed ID: 21752880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
    Aydin MU; Aygul N; Altunkeser BB; Unlu A; Taner A
    Atherosclerosis; 2015 Apr; 239(2):439-43. PubMed ID: 25697576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome.
    Zhang X; Zeng X; Dong L; Zhao X; Qu X
    World J Urol; 2015 Dec; 33(12):2071-7. PubMed ID: 25850975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moderate statin treatment reduces prebeta-1 high-density lipoprotein levels in dyslipidemic patients.
    Quinn AG; Schwemberger R; Stock EO; Movsesyan I; Axtell A; Chang S; Ishida BY; Malloy MJ; Kane JP; Pullinger CR
    J Clin Lipidol; 2017; 11(4):908-914. PubMed ID: 28558949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Atorvastatin inhibits the atherosclerotic lesion induced by tumor necrosis factor-like weak inducer of apoptosis in apolipoprotein E deficient mice].
    Fernández-Laso V; Sastre C; Egido J; Martín-Ventura JL; Blanco-Colio LM
    Clin Investig Arterioscler; 2015; 27(1):17-25. PubMed ID: 25027757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
    Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk.
    Laufs U; Karmann B; Pittrow D
    Clin Res Cardiol; 2016 Sep; 105(9):783-90. PubMed ID: 27120330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis.
    Kabel AM; Abd Elmaaboud MA; Albarraq AA
    Prostaglandins Leukot Essent Fatty Acids; 2015 May; 96():1-9. PubMed ID: 25541279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/stroke: a case-control study.
    Marchione P; Vento C; Morreale M; Izzo C; Maugeri A; Manuppella F; Romeo T; Giacomini P
    J Stroke Cerebrovasc Dis; 2015 Jan; 24(1):138-43. PubMed ID: 25440329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound.
    Yamada K; Yoshimura S; Kawasaki M; Enomoto Y; Asano T; Minatoguchi S; Iwama T
    Cerebrovasc Dis; 2009; 28(4):417-24. PubMed ID: 19707015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.
    Pattanaik S; Malhotra S; Sharma YP; Pandhi P
    J Cardiovasc Pharmacol; 2012 May; 59(5):479-84. PubMed ID: 22569288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Atorvastatin in treatment of patients with coronary heart disease and dislipidemiya and high general risk: efficiency and safety estimation. Design and main results of ATLANTIKA].
    Mareev VIu; Belenkov IuN; Oganov RG; Barbik-Zhagar B
    Kardiologiia; 2008; 48(11):4-13. PubMed ID: 19076074
    [No Abstract]   [Full Text] [Related]  

  • 34. [Difference in efficacy of dyslipidaemia treatment in obese and not obese women. Analysis of date from 3ST-POL study].
    Wełnicki M; Śliż D; Filipiak KJ; Szeligowska J; Naurszewicz M; Siebert J; Mamcarz A
    Przegl Lek; 2016; 73(6):353-8. PubMed ID: 29668197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
    Jafari M; Ebrahimi R; Ahmadi-Kashani M; Balian H; Bashir M
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):123-6. PubMed ID: 12808485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total lipid management and cardiovascular disease in the dyslipidemia international study.
    Ferrières J; Amber V; Crisan O; Chazelle F; Jünger C; Wood D
    Cardiology; 2013; 125(3):154-63. PubMed ID: 23736147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: a longitudinal study during atorvastatin treatment.
    Guasti L; Maresca AM; Schembri L; Rasini E; Dentali F; Squizzato A; Klersy C; Robustelli Test L; Mongiardi C; Campiotti L; Ageno W; Grandi AM; Cosentino M; Marino F
    BMC Cardiovasc Disord; 2016 Jan; 16():26. PubMed ID: 26822994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
    Cosin Sales J; Fuentes Jiménez FJ; Mantilla Morató T; Ruiz E; Becerra V; Aceituno S; Ferrario MG; Lizán L; Gracia A
    Clin Investig Arterioscler; 2015; 27(5):228-38. PubMed ID: 25640158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atorvastatin treatment is associated with increased BDNF level and improved functional recovery after atherothrombotic stroke.
    Zhang J; Mu X; Breker DA; Li Y; Gao Z; Huang Y
    Int J Neurosci; 2017 Jan; 127(1):92-97. PubMed ID: 26815593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.